Skip to content
Clinical Trials – home
SloveniaBack to Slovenia

Clinical trials in Jesenice – page 3

82 clinical trials in Jesenice, Slovenia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SloveniaOur site in SloveniaKlinicnaPreskusanja.si(opens in a new tab)
Jesenice at a glance
82
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

82 trials in Jesenice

Open in trial search

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Pharmacosmos A/S

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Pneumonia

Recruiting

Study of Trimodulin for Adults Hospitalized with Severe Community-Acquired Pneumonia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Aortic valve stenosis

Not yet recruiting

A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ataciguat
  • Sponsor:Kardigan Inc.

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Pulmonary hypertension

Not yet recruiting

A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Levosimendan
  • Sponsor:Tenax Therapeutics Inc.

Other cities in Slovenia

The busiest research cities in the country

All 18 cities in Slovenia

Clinical research in Jesenice

What the registry says about research in the country

01 Heart Failure Prevention & Treatment

Innovative research focusing on cardiovascular health through combination therapy approaches. Studies are evaluating new treatments to reduce the risk of heart failure events and improve patient outcomes.

  • Prevention of Heart Failure
  • Cardiovascular Death Risk Reduction
  • Combination Therapy Assessment

These trials aim to advance treatment options for patients at risk of developing heart failure.

02 Lipid Management

Research examining the effectiveness of treatments for hyperlipidemia, focusing on LDL cholesterol reduction in high-risk patients. Studies evaluate both single and combination medication approaches.

  • LDL-C Reduction Strategies
  • High-Risk Patient Management
  • Cardiovascular Risk Prevention

Trials target optimal cholesterol management for cardiovascular disease prevention.

03 Blood Pressure Management

Studies investigating advanced treatments for arterial hypertension, with a focus on innovative combination therapies and 24-hour blood pressure control.

  • 24-Hour BP Control
  • Multi-Drug Combinations
  • Hypertension Management

Research aims to optimize blood pressure control through single-pill combination treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.